Titre
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Ciurea, A.
Auteure/Auteur
Papagiannoulis, E.
Auteure/Auteur
Bürki, K.
Auteure/Auteur
von Loga, I.
Auteure/Auteur
Micheroli, R.
Auteure/Auteur
Möller, B.
Auteure/Auteur
Rubbert-Roth, A.
Auteure/Auteur
Andor, M.
Auteure/Auteur
Bräm, R.
Auteure/Auteur
Müller, A.
Auteure/Auteur
Dan, D.
Auteure/Auteur
Kyburz, D.
Auteure/Auteur
Distler, O.
Auteure/Auteur
Scherer, A.
Auteure/Auteur
Finckh, A.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1468-2060
Statut éditorial
Publié
Date de publication
2021-02
Volume
80
Numéro
2
Première page
238
Dernière page/numéro d’article
241
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
To investigate whether the transient reduction in rheumatology services imposed by virus containment measures during the COVID-19 pandemic was associated with disease worsening in axial spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA).
Patient-reported disease activity assessed during face-to-face visits and/or via a smartphone application were compared between three periods of each 2 months duration (before, during and after the COVID-19-wave) from January to June 2020 in 666 patients with axSpA, RA and PsA in the Swiss Clinical Quality Management cohort.
The number of consultations dropped by 52%, whereas the number of remote assessments increased by 129%. The proportion of patients with drug non-compliance slightly increased during the pandemic, the difference reaching statistical significance in axSpA (19.9% vs 13.2% before the pandemic, p=0.003). The proportion of patients with disease flares remained stable (<15%). There was no increase in mean values of the Bath Ankylosing Disease Activity Index, the Rheumatoid Arthritis Disease Activity Index-5 and the Patient Global Assessment in patients with axSpA, RA and PsA, respectively.
A short interruption of in-person patient-rheumatologist interactions had no major detrimental impact on the disease course of axSpA, RA and PsA as assessed by patient-reported outcomes.
Patient-reported disease activity assessed during face-to-face visits and/or via a smartphone application were compared between three periods of each 2 months duration (before, during and after the COVID-19-wave) from January to June 2020 in 666 patients with axSpA, RA and PsA in the Swiss Clinical Quality Management cohort.
The number of consultations dropped by 52%, whereas the number of remote assessments increased by 129%. The proportion of patients with drug non-compliance slightly increased during the pandemic, the difference reaching statistical significance in axSpA (19.9% vs 13.2% before the pandemic, p=0.003). The proportion of patients with disease flares remained stable (<15%). There was no increase in mean values of the Bath Ankylosing Disease Activity Index, the Rheumatoid Arthritis Disease Activity Index-5 and the Patient Global Assessment in patients with axSpA, RA and PsA, respectively.
A short interruption of in-person patient-rheumatologist interactions had no major detrimental impact on the disease course of axSpA, RA and PsA as assessed by patient-reported outcomes.
Sujets
PID Serval
serval:BIB_7CB0EF3F30FE
PMID
Open Access
Oui
Date de création
2020-09-26T14:18:42.767Z
Date de création dans IRIS
2025-05-21T00:00:27Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
annrheumdis-2020-218705.pdf
Version du manuscrit
preprint
Taille
527.59 KB
Format
Adobe PDF
PID Serval
serval:BIB_7CB0EF3F30FE.P001
Somme de contrôle
(MD5):66f302c0afe126a27bd97419599a1b59